Journal Article

A comprehensive approach to lifestyle intervention based on a calorie-restricted diet ameliorates liver fat in overweight/obese patients with NAFLD: a multicenter randomized controlled trial in China

Jin, Piaopiao, Cao, Suyan, Tian, Cuihuan, Zhang, Zhimian, Li, Nan, Wu, Xiangming, Wang, Yan, Liu, Yuping, Zeng, Chang, Weng, Min, Liu, Zhong, Sun, Ping, Yang, Rui, Liu, Chenbing, Zeng, Qiang

2024

Overview

Background Nonalcoholic fatty liver disease (NAFLD) is a globally increasing health epidemic. Lifestyle intervention is recommended as the main therapy for NAFLD. However, the optimal approach is still unclear. This study aimed to evaluate the effects of a comprehensive approach of intensive lifestyle intervention (ILI) concerning enhanced control of calorie-restricted diet (CRD), exercise, and personalized nutrition counseling on liver steatosis and extrahepatic metabolic status in Chinese overweight and obese patients with NAFLD. Methods This study was a multicenter randomized controlled trial (RCT) conducted across seven hospitals in China. It involved 226 participants with a body mass index (BMI) above 25. These participants were randomly assigned to two groups: the ILI group, which followed a low carbohydrate, high protein CRD combined with exercise and intensive counseling from a dietitian, and a control group, which adhered to a balanced CRD along with exercise and standard counseling. The main measure of the study was the change in the fat attenuation parameter (FAP) from the start of the study to week 12, analyzed within the per-protocol set. Secondary measures included changes in BMI, liver stiffness measurement (LSM), and the improvement of various metabolic indexes. Additionally, predetermined subgroup analyses of the FAP were conducted based on variables like gender, age, BMI, ethnicity, hyperlipidemia, and hypertension. Results A total of 167 participants completed the whole study. Compared to the control group, ILI participants achieved a significant reduction in FAP (LS mean difference, 16.07 [95% CI: 8.90–23.25] dB/m) and BMI (LS mean difference, 1.46 [95% CI: 1.09–1.82] kg/m 2 ) but not in LSM improvement (LS mean difference, 0.20 [95% CI: -0.19–0.59] kPa). The ILI also substantially improved other secondary outcomes (including ALT, AST, GGT, body fat mass, muscle mass and skeletal muscle mass, triglyceride, fasting blood glucose, fasting insulin, HbA1c, HOMA-IR, HOMA-β, blood pressure, and homocysteine). Further subgroup analyses showed that ILI, rather than control intervention, led to more significant FAP reduction, especially in patients with concurrent hypertension ( p  < 0.001). Conclusion In this RCT, a 12-week intensive lifestyle intervention program led to significant improvements in liver steatosis and other metabolic indicators in overweight and obese Chinese patients suffering from nonalcoholic fatty liver disease. Further research is required to confirm the long-term advantages and practicality of this approach. Trial registration This clinical trial was registered on ClinicalTrials.gov (registration number: NCT03972631) in June 2019.

• Publisher: BioMed Central,BioMed Central Ltd,BMC
• Subject: Adult / blood glucose / blood pressure / Blood sugar / body fat / Body Mass Index / Caloric Restriction - methods / carbohydrates / Care and treatment / China / Clinical Nutrition / Clinical trials / Complications and side effects / Counseling - methods / Diet / dietitians / Exercise / Exercise - physiology / Fatty liver / Female / gender / Glycosylated hemoglobin / Health aspects / Health Promotion and Disease Prevention / High protein / homocysteine / Hospitals / Humans / hyperlipidemia / Hypertension / insulin / Life Style / lifestyle / Lifestyle intervention / liver / Liver - metabolism / Liver diseases / Low carbohydrate / Low-calorie diet / Male / Medical research / Medicine / Medicine & Public Health / Medicine, Experimental / Middle Aged / Muscles / nationalities and ethnic groups / Non-alcoholic Fatty Liver Disease - complications / Non-alcoholic Fatty Liver Disease - diet therapy / Non-alcoholic Fatty Liver Disease - therapy / Obese / Obesity / Obesity - complications / Obesity - diet therapy / Obesity - therapy / Overweight / Overweight - complications / Overweight - diet therapy / Overweight - therapy / Patient outcomes / randomized clinical trials / skeletal muscle / therapeutics / triacylglycerols / Type 2 diabetes